On October 23, 2020 BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, reported that it will host a virtual R&D Day on 06 November 2020 from 13.00 CET (Press release, BerGenBio, OCT 23, 2020, View Source;06-november-2020-301158567.html [SID1234568941]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will feature independent experts highlighting the role of AXL kinase as an essential mediator of the biological mechanisms underlying life-threatening diseases. The presentations will focus on the role of AXL in specific disease areas including oncology, fibrosis and infectious disease such as COVID-19. Each presentation will be followed by a Q&A session.

A preliminary program for the event is outlined below. To register, please click here.

Preliminary Agenda

13:00

Introduction – Richard Godfrey, Chief Executive Officer, BerGenBio

13:10

AXL in AML/MDS – Professor Sonja Loges, Director, Department of Personalised Oncology, University Hospital Mannheim and Division of Personalised Medical Oncology, German Research Center – DKFZ (Heidelberg, Germany)

13:40

AXL in lung cancer – Dr Matthew Krebs, Clinical Senior Lecturer in Experimental Cancer Medicine and Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust (Manchester, UK)

14:10

AXL and viruses/COVID-19 – Professor Wendy Maury, Professor of Microbiology and Immunology, University of Iowa (Iowa City, USA)

14:40

AXL in fibrosis/IPF – Professor Cory Hogaboam, Professor of Medicine, Cedars-Sinai Medical Center (Los Angeles, USA)

15:10

Bemcentinib clinical development plan – Hani Gabra, Chief Medical Officer, BerGenBio

15:25

Concluding remarks – Richard Godfrey, Chief Executive Officer, BerGenBio

For further information, please contact Consilium Strategic Communications at [email protected] or [email protected]

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying life-threatening diseases. In cancer, AXL suppresses the body’s immune response to tumours and drives cancer treatment failure across many indications. AXL expression defines a very poor prognosis subgroup in most cancers. AXL inhibitors, therefore, have potential high value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities. Research has also shown that AXL mediates other aggressive diseases.